Wczytywanie kursów wyceny...
Prognoza
| Kupuj |
4 |
| Trzymaj |
9 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
Satsuma Technologie announces auditor change after strategic review
Satsuma Technologie said that Kreston Reeves LLP has resigned its appointment following discussions as part of a comprehensive strategic review and the appointment of a new leadership team in summer 2025. The board has launched a formal selection process for a new auditor to support the company’s growth plans. A statement from Kreston Reeves on its resignation will be circulated and published in accordance with the Companies Act 2006, and a new appointment will be announced in due course. » Więcej na de.investing.com
Satsuma Technologie raises £163.6 million through successful convertible bond issuance
Satsuma Technologie has raised £163.6 million by placing a second secured convertible bond, significantly surpassing its minimum target. The financing attracted prominent investors and allowed some to invest in Bitcoin instead of cash. The funds will be used for business expansion and to strengthen the company's Bitcoin-based treasury strategy. » Więcej na de.investing.com
Tao Alpha becomes Satsuma Technology and adopts new ticker SATS.L
Tao Alpha PLC is changing its name to Satsuma Technology PLC and adopting the new ticker symbol SATS.L on the London Stock Exchange. The rebranding is intended to highlight the company's focus on decentralized AI services and a Bitcoin-based treasury strategy, while existing shareholder rights remain unaffected. CEO Matthew Lodge emphasizes that this marks a step into a new phase of operational maturity. » Więcej na de.investing.com
Historyczne dywidendy Dywidendy
Wszystkie wskaźniki dywidendowe Wszystkie wskaźnikiDane finansowe spółki
| (EUR) | 2022 | |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | 0 | - |
| Zysk netto | -64,48 mln | 43,02% |
| EBITDA | -54,36 mln | 22,13% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 32,39 mln € |
Liczba akcji | 33,15 mln |
Maksimum/minimum z 52 tygodni | 7,18 € - 0,52 € |
| Dywidendy | Nie |
Beta | 0,10 |
C/Z (PE Ratio) | -0,51 |
PEG (PEG Ratio) | 0,05 |
C/WK (PB Ratio) | -0,17 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Satsuma Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige therapeutische Produkte für die akute Behandlung von Migräne entwickelt. Der führende Produktkandidat des Unternehmens ist STS101, eine Arzneimittel-Geräte-Kombination aus einer patentrechtlich geschützten Trockenpulverformulierung von Dihydroergotaminmesylat, die sich in SUMMIT-Phase-3-Wirksamkeitsstudien befindet und mit einem patentrechtlich geschützten, vorgefüllten Einweg- und Nasenspritzgerät selbst verabreicht werden kann. Satsuma Pharmaceuticals, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.
| Nazwa | Satsuma Pharmaceuticals |
| CEO | John A. Kollins MBA |
| Siedziba | South San Francisco,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 13.09.2019 |
| Pracownicy | 25 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | STSA |
